Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lonial meet in San Diego at the American Society of Hematology 2018 conference for an educational multiple myeloma panel discussion.
Their talk covers the results of the Tourmaline-MM3 study – maintenance therapy with the oral proteasome Inhibitor Ixazomib following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.
Prof Mateos chairs the discussion, opening the talk by asking Dr Lonial to describe the rationale for the study and why a new option of maintenance therapy is needed for the treatment of newly diagnosed multiple myeloma patients.
She then ask Prof Beksac to comment on her experience of Proteasome Inhibitor use in clinic. Beksac outlines the issue with tolerability that is often found with drugs used in the maintenance setting, and explains why it makes sense to use an oral therapy in this setting.
The discussion then turns to Prof Chng who comments on the trial’s efficacy results vs placebo, before Prof Mateos prompts Dr Lonial to outline Ixazomib’s safety profile based on the results from the trial.
The panel move on to discuss the rationale for setting the duration of maintenance to two years in the study and how this could have impacted the results, before outlining the specific patient subgroups that benefitted from the therapy.
Prof Mateos then directs the discussion to the future use of Ixazomib, where this could be used in the treatment pathway for patients with newly diagnosed multiple myeloma, and how its role compares to other drugs used to treat this patient group.
The discussion is finalised by summarising the key findings from the Tourmaline-MM3 study – that Ixazomib is found to be an effective maintenance therapy for the treatment of patients with newly diagnosed Multiple Myeloma following autologous stem cell transplantation, and has the potential to be used as a standard of care treatment.
|Rationale for the Tourmaline-MM3 study|
|Use of bortezomib in the clinic|
|Efficacy of Ixazomib|
|Response of Ixazomib as a maintenance therapy|
|Safety profile of Ixazomib|
|Duration of maintenance therapy in the Tourmaline-MM3 study|
|Treatment options for specific patient sub-groups|
This programme has been supported by an unrestricted educational grant from Takeda Pharmaceutical Company